TheProfitWatch

GILD - Gilead Sciences Inc

Day 1m 10m 60m PreMarket Market AfterHours Gap
125.44 2.25 (1.79%) 0.03 (0.02%) 0.13 (0.1%) -0.03 (-0.02%) 0.11 (0.09%) 2.35 (1.87%) -0.65 (-0.52%) -0.12 (-0.1%)

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
1.57
Diluted EPS:
1.56
Basic P/E:
81.3312
Diluted P/E:
81.8526
RSI(14) 1m:
59.85
VWAP:
127.73
RVol:

Events

Period Kind Movement Occurred At

Related News